• Alexia Fernández-Ruiz, Isabel Sanjoaquín-Conde, Santiago Letona-Carbajo, Julio José Lambea-Sorrosal, and María José Crusells-Canales.
• Servicio de Oncología Médica, Hospital General San Jorge, Huesca, España. Electronic address: afdezru@gmail.com.
• Med Clin (Barc). 2020 Apr 24; 154 (8): 295-300.

Background And ObjectiveAfter the introduction of antiretroviral therapy, a decrease in AIDS defining cancers (ADCs) is observed, while non-AIDS-defining cancers (NADCs) have increased in HIV-infected patients (HIP). We have little information about the prognosis and associated risk factors. We studied survival and its relationship with immunodeficiency after the diagnosis of ADC or NADC.Material And MethodsObservational, retrospective study of 788 HIP of whom 133 developed a malignancy between 2000-2016. Malignancies were divided into ADCs or NADCs and degree of immunodeficiency according to the CD4 T lymphocyte count> or Results149 malignancies were diagnosed in 133 HIP: 41.4% ADCs and 58.6 NADCs. The most frequent tumour was NHL (21.1%), followed by lung carcinoma (15%). HCV was positive in 50.4% and 65.4% were smokers. Thirty-nine point one percent had a CD4 T lymphocyte count ConclusionsThe most frequent types of tumours in HIP differ from those in the general population, probably due to oncogenic risk factors. CD4 T lymphocyte count Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

6 keywords...

hide…